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HSP70 Protects against TNF-Induced Lethal
Inflammatory Shock
One of the major HSPs is HSP70, named after its
molecular mass of approximately 70 kDa. The subfamily,
consisting of at least seven members in the mouse,
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contains both constitutive and inducible forms (Lind-1Department of Molecular Biology
quist and Craig, 1988). As constitutive member in theUnit of Mouse Molecular Genetics
mouse, the 70 kDa HS cognate HSC70 (Giebel et al.,Flanders Interuniversity Institute
1988), as well as the 75 kDa and 78 kDa glucose-regu-for Biotechnology and
lated proteins GRP75 (Domanico et al., 1993) and GRP78University of Ghent
(Kozutsumi et al., 1989), has been described. HSP70.1K.L. Ledeganckstraat 35
and HSP70.3 are both inducible (Hunt et al., 1993), while9000 Ghent
the spermatocyte-specific HSP70.2 is expressed duringBelgium
the meiotic phase of spermatogenesis (Allen et al.,2 Department of Molecular Biology and Immunology
1988). The testis-specific HSC70 (HSC70t) is expressedNational Institute of Agrobiological Sciences
in postmeiotic spermatids (Matsumoto and Fujimoto,2-1-2 Kannondai, Tsukuba
1990). Recently, several reports have dealt with the pro-305-8602 Ibaraki
tecting capacities of HSP70 against various toxic stimuli.Japan
HS was demonstrated to prevent lethality induced by
lipopolysaccharide (LPS) in rats and mice (Ryan et al.,
1992; Hotchkiss et al., 1993). This protection also corre-Summary
lated with HSP70 upregulation in several organs (Hotch-
kiss et al., 1993). Ischemic preconditioning of the liverThe heat shock (HS) response is a universal response
also leads to strong HSP70 induction, which results inactivated after exposure to various stimuli. The major
resistance to subsequent ischemia-reperfusion injury ofHS protein (HSP) is the 72 kDa HSP70 with strong
the liver in the rat (Kume et al., 1996).homology in different eukaryotic species. We demon-
HSP70-transgenic mice were generated a few yearsstrate that HS treatment of mice leads to a strong
ago (Marber et al., 1995). In these mice, the rat hsp70induction of HSP70 in several organs and confers sig-
gene was placed under control of an hCMV-IE enhancernificant protection against lethality induced by tumor
and -actin promoter, resulting in strong constitutivenecrosis factor (TNF). HS prevents high production
expression in cardiac muscle, skeletal muscle, andof interleukin-6 and nitric oxide and reduces severe
brain. These mice display resistance against severaldamage and apoptosis of the enterocytes in the bowel.
models of heart ischemic injury (Marber et al., 1995;Mice deficient in the inducible hsp70.1 gene were no
Hutter et al., 1996; Trost et al., 1998). Also by means oflonger protected by HS treatment. We show that HS
adenoviruses, the protecting capacity of HSP70 againstcan be applied successfully in an antitumor protocol
myocardial ischemia was demonstrated (Mestril et al.,based on TNF and interferon-, leading to a significant
1996). Another argument for a protective role of HSP70inhibition of lethality but not to a reduction of antitu-
against LPS toxicity was provided by the constructionmoral capacity.
of HS transcription factor-1 (HSF-1) knockout mice
(McMillan et al., 1998). HSFs regulate the stress-induc-Introduction
ible synthesis of HSPs (Morimoto, 1998). HSF-1 knock-
out mice show an increased sensitivity to LPS-induced
Heat shock (HS) proteins (HSPs) are conserved mole-
toxicity and lethality (Xiao et al., 1999). Finally, there are
cules present in all prokaryotes and eukaryotes studied
numerous reports clearly stating a protecting role of
so far. Under normal physiological conditions, the ex- HSP70 in vitro by means of HS induction or HSP70
pression of these proteins is very low (Craig and Gross, overexpression (Ja¨a¨ttela¨ et al., 1989; Larrick and Wright,
1991). In stress situations, a very strong synthesis of 1990; Margulis et al., 1991) against toxicity induced by
these proteins has been observed (Lindquist and Craig, several cytokines.
1988). These stress stimuli can either be physiological In this study, we evaluated the role of HSP70 induction
(growth factors and hormonal stimulation), environmen- by means of whole-body HS in the toxicity and lethality
tal (HS, heavy metals, and ultraviolet radiation), or patho- induced by TNF in mice. TNF is a pleiotropic cytokine
logical (inflammation, autoimmune reactions, and viral, mainly produced by activated macrophages and has a
bacteriological, or parasitic infections). The main func- strong antitumor activity both in vitro and in vivo (Aggar-
tion of HSPs is to operate as intracellular chaperones wal and Natarajan, 1996). Systemic administration of
for aberrantly folded or mutated proteins and to provide TNF at relatively high doses induces a systemic inflam-
cytoprotection against the stress conditions mentioned matory response syndrome, characterized by bowel ne-
above. For this reason, the presence of a cellular stress crosis, liver damage, and severe hypotension, leading
response in cancer cells reduces their sensitivity to to death (Tracey and Cerami, 1993). We demonstrate
chemical stress caused by insufficient tumor perfusion that application of HS in mice induces HSP70 in several
or chemotherapy (Jolly and Morimoto, 2000). organs and significantly leads to attenuation of TNF-
induced lethality. We further show that HSP70 induction
prevents interleukin-6 (IL-6) and nitric oxide (NO) induc-3 Correspondence: claude.libert@dmb.rug.ac.be
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Figure 1. Generation of hsp70.1/ Mice
(A) Targeting strategy.
(B) Southern blot analysis of representative
mouse tail DNA digested with ApaI and hy-
bridized with probe A.
(C) Northern blot analysis of representative
HS-induced mouse embryonic fibroblast
mRNA hybridized with probe B. The hsp70.1-
NeoR fusion mRNA was calculated to be 2.4
kb based on the sequence of the targeting
vector.
tion in the serum as well as apoptosis and tissue damage ences between knockout and wt mice under specific
pathogen-free conditions.of the intestinal tract. We provide direct proof for the
involvement of HSP70 using hsp70.1-deficient mice. Fi-
nally, we provide evidence for a potential application of HS Treatment of Mice Induces HSP70
in Several OrgansHS in antitumor treatment based on TNF and interferon-
(IFN-). A number of different methods to induce HS have been
described previously. Some of these methods demon-
strate HSP70 induction in several organs in rats andResults
mice (Hotchkiss et al., 1993; Kume et al., 1996). First,
we evaluated the increase in core body temperatureGeneration of hsp70.1/ Mice
The hsp70.1 genomic structure, the targeting vector, during the HS induction method used. Mice (n  12)
were HS treated for 20 min. The rectal body temperatureand the targeted allele are shown in Figure 1A. After
restriction digest of genomic DNA with ApaI and hybrid- was monitored from HS start until 10 min after HS end
and was recorded every 2 min. The body temperatureization with probe A, a 6.7 kb fragment was obtained
for wild-type (wt) mice. The targeted allele provided a increased in a linear way up to 10 min after HS start and
then displayed a plateau level of about 41.5C until HSfragment of 9.3 kb due to loss of the unique ApaI site
in the hsp70.1 gene by homologous recombination with end. .6 min after HS end, all mice had regained their
normal body temperature of approximately 37C (Figurethe targeting vector (Figure 1A). The latter was con-
structed with the neomycin-resistant (NeoR) gene with- 2A). To test whether the HS conditions used had led to
a strong HSP70 induction, mice were HS treated for 20out promoter as positive selection marker. Thus, the
NeoR gene can be expressed from the hsp70.1 gene min; 2, 6, 12, 24, 48, 72, or 96 hr thereafter, mice were
killed. Seven organs (liver, lung, duodenum, jejunum,promoter, provided accurate homologous recombina-
tion had occurred. The frequency of the homologous colon, heart, and kidney) were removed and homoge-
nized in glycerol buffer. The homogenates were ana-recombination was 2/78 of G418-resistant clones. Two
cloned embryonic stem (ES) cells were injected into lyzed by Western blot for HSP70 presence (Figure 2B).
HSP70 induction in the liver was clear at the earliestblastocysts. The resulting chimera mice bred so that
hsp70.1 heterozygous mice (/) were obtained. After time point. The expression was maximal between 6 and
24 hr following HS and diminished after 48 hr. In controleight generations of backcross with C57BL/6J mice,
hsp70.1 homozygous mice (/) were generated from mice (not subjected to HS), no detectable HSP70 was
present. A similar HSP70 induction profile was also ob-crossbreeding between heterozygotes. Hsp70.1 (/),
(/), and (/) genotypes were born according to served in lung samples, high levels being reached from
6 to 24 hr after HS. In the duodenum, HSP70 was de-expected Mendelian ratios of 1:2:1. Screening of ES
cells and mice was performed by Southern blot, yielding tected only between 6 and 12 hr after HS. A very high
expression was also observed in the jejunum 6 and 12a single fragment of 6.7 kb for wt, a 9.3 kb fragment for
knockout, and both fragments for heterozygote mice hr after HS. In the colon, the expression was low at 2
hr but remained strong 6 to 48 hr after HS. In the heart,(Figure 1B). To further confirm the targeted disruption
of the hsp70.1 gene, we examined hsp70.1 mRNA tran- there was only induction 24 hr after HS, while no HSP70
could be detected in the kidney (results not shown).scription by Northern blot analysis (Figure 1C). Cultures
of wt, homozygous, and heterozygous embryonic fibro- These data demonstrate that the method used for HS
application results in a high increase in core body tem-blasts were cultured at 42C for 1 hr, followed by 12 hr
incubation at 37C. Probe B, specific for the hsp70.1 perature and in a strong HSP70 induction in several
organs.gene, hybridized with the 3.0 kb mRNA for the wt allele
and the 2.4 kb mRNA for the targeted allele. These re-
sults confirm that correct homologous recombination HS Induction Prevents TNF-Induced Lethality
Based on our data on HSP70 induction, we evaluatedhad occurred in ES cells. Hsp70.1 gene knockout mice
developed normally and were fertile. Gross and histo- the effect of HSP70 upregulation on TNF-induced lethal-
ity. In most of the organs tested, the induction is maximalpathological observations revealed no apparent differ-
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Figure 2. Increase in Body Temperature and HSP70 Induction in Tissue Homogenates of Mice after Whole-Body HS
(A) Rectal body temperature was monitored and recorded (, n  12) during HS until 10 min after HS (black line, HS induction period).
(B) Mice were subjected to HS and killed at different time points. Expression of HSP70 was analyzed by Western blotting.
from 6 to 24 hr after HS. Therefore, we subjected mice IL-6. High levels of nitrate and nitrite (stable end prod-
ucts of NO) and IL-6 were observed in the serum afterto HS and challenged them i.v. with 15 g TNF, i.e., a
100% lethal dose, 6 hr (n  8), 12 hr (n  45), or 24 hr TNF challenge (Van Molle et al., 1997). It is believed that
sustained levels of IL-6 (Libert et al., 1990) and NO are(n  6) later. Mice were also challenged with TNF 2 hr
(n  6) or 48 hr (n  6) after HS (low or no expression representative of a lethal outcome. First, we studied
the effect of HS treatment on the drop in temperatureof HSP70). As controls, mice (n  44) were challenged
with TNF without prior HS. We show that mice are signifi- induced by TNF injection. Mice were HS pretreated (n
12) and challenged i.v. 12 hr later with 15g TNF. Controlcantly protected from TNF-induced lethality when
treated with TNF 12 hr after HS (Figure 3): a statistically mice (n  12) received TNF without prior HS. HS-pre-
treated mice have significantly less TNF-induced hypo-significant difference was observed, both in survival
time (p  0.0001) and in final lethality (12/45 dead HS- thermia compared to mice challenged with TNF without
prior HS treatment (p  0.001 from 6 to 28 hr after thepretreated mice versus 44/44 dead control mice; p 
0.0001). When mice were challenged with TNF 6 hr after challenge) (Figure 4A). In both groups the body tempera-
ture dropped, but HS-pretreated mice recovered be-HS, a highly significant delay in lethality (p  0.0066)
was found. However, eventually all mice died as a result tween 12 and 24 hr after the challenge. By 48 hr after
the TNF challenge, all HS-pretreated surviving mice hadof TNF toxicity. No significant protection was observed
when mice were challenged 2, 24, or 48 hr after HS. regained normal body temperatures. In order to study
the effect of HS on TNF-induced NO and IL-6, mice wereFrom these data we conclude that mice are maximally
protected 12 hr after HS treatment. pretreated with HS (n  30) and challenged 12 hr later
i.v. with 15 g TNF. Control mice (n  30) were chal-
lenged i.v. with TNF without HS pretreatment. One,Effect of HS on TNF-Induced Hypothermia,
NO, and IL-6 three, six, nine, twelve, or twenty-four hours after the
challenge, blood was taken by cardial puncture (six miceInjecting mice with a high (lethal) dose of TNF results in
massive production of NO (leading to hypotension) and per time point) and serum was prepared. HS pretreat-
ment significantly reduced the NO production (Figure
4B). A highly significant difference was found 9 hr (p 
0.0019), 12 hr (p  0.0001), and 24 hr (p  0.0001) after
the challenge for HS-pretreated versus control mice. We
also observed a strong inhibiting effect of HS on TNF-
induced IL-6 production. IL-6 induction (Figure 4C) was
significantly lower in HS-pretreated mice than in control
mice at 3 hr (p  0.0233), 6 hr (p  0.0025), 9 hr (p 
0.0042), 12 hr (p  0.0002), and 24 hr (p  0.0001) after
TNF challenge. These data demonstrate that HS pre-
treatment significantly prevents TNF-induced NO and
IL-6 production.
HS Prevents TNF-Induced Bowel Damage
Challenging mice with TNF results in severe bowel swell-
ing and damage (Tracey et al., 1986; Piguet et al., 1998).
Figure 3. HS Treatment 12 Hr before TNF Challenge Prevents Le-
To evaluate the HS effect on TNF-induced bowel dam-thality
age, mice were subjected to HS (n  12), followed after
Mice were subjected to HS and challenged i.v. with 15 g TNF 2 hr
12 hr by an i.v. challenge with 15 g TNF. Control mice(, n  6), 6 hr (, n  8), 12 hr (, n  45), 24 hr (, n  6), or 48
(n 12) were challenged i.v. with 15g TNF without priorhr (H17009, n  6) after HS. Controls were challenged with TNF without
prior HS (, n  44). HS and killed after 1 hr. The small intestine (duodenum,
Immunity
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mice treated with TNF without prior HS) (Figure 5A).
The small intestine is known to increase dramatically in
weight at early time points (0.5–1.5 hr) after TNF chal-
lenge due to excessive fluid exudation (Piguet et al.,
1998).
In order to investigate in more detail the TNF-induced
tissue damage and HS-induced protection, parts of the
jejunum were removed and 20% homogenates (n  6)
were made. The extent of apoptosis was determined
using a DNA fragmentation ELISA. The degree of back-
ground apoptosis in PBS-treated mice was regarded as
100%, which is a measure for normal physiologically
occurring apoptosis. TNF significantly increased the ex-
tent of apoptosis in the jejunum (p0.0029 as compared
to PBS treatment), while HS pretreatment significantly
inhibited this tissue damage (p  0.0232 as compared
to TNF treatment without prior HS) (Figure 5A). Since
activation of caspases is a typical hallmark for apopto-
sis, we also determined the caspase activity in the ho-
mogenates. Cleavage of the chromogenic substrate
acetyl-Asp(OMe)-Glu(OMe)-Val-Asp(OMe)-aminomethyl-
coumarin (ac-DEVD-amc) is a measure of caspase-3
and caspase-7 activity, both known as executioner cas-
pases. In homogenates of mice treated with PBS (n 
6), there was some background caspase-like activity,
but that activity was significantly increased after TNF
challenge (p  0.0053 as compared to PBS treatment)
(Figure 5A). HS pretreatment prevents apoptosis, since
DEVDase activity was significantly lower as compared
to a TNF challenge without prior HS (p  0.0030).
To investigate the TNF-induced tissue damage at the
cellular level, parts of the jejunum were removed and
stained with hematoxylin/eosin, and analyzed by immu-
nohistochemistry for HSP70 induction or analyzed for
apoptosis by TUNEL assay. Treatment with TNF (Figure
5C) resulted in severe damage of the jejunum compared
to untreated animals (Figure 5B). The villi are flattened
due to loss of their upper part with denudation at the
top. The crypts are distended and contain mucus and
debris. We also observed loss of goblet cells. When mice
were HS-pretreated 12 hr before the TNF challenge, the
damage was markedly reduced (Figure 5D). There is
less shortening of the villi, and the crypts retain their
normal architecture. Tissue sections were also analyzed
by TUNEL assay to stain apoptotic cells. In control mice,
no TUNEL staining was found (Figure 5E); in contrast,
the top of the villi of TNF-treated mice showed positive
TUNEL staining, as visualized by brown nucleus staining
(Figure 5F, arrows). In HS-pretreated mice, TUNEL stain-
ing was completely absent (Figure 5G). With immunohis-
Figure 4. Effect of HS on TNF-Induced Hypothermia as well as TNF- tochemistry we only observed detectable HSP70 in the
Induced NO and IL-6 Production
jejunum from HS-treated mice (Figure 5J), while only(A) Mice were subjected to HS and challenged i.v. after 12 hr with
background staining was detected in PBS-injected mice15 g TNF (, n  12). Control mice were challenged i.v. with 15
(Figure 5H) and TNF-injected mice (Figure 5I) withoutg TNF without prior HS (, n  12). Rectal body temperature was
measured at the indicated time points after TNF treatment. prior HS. The expression was maximal at the top of the
(B–C) Mice were subjected to HS and challenged i.v. after 12 hr with villi, demonstrating that HSP70-expressing cells were
15 g TNF (, n  30). Control mice were challenged i.v. with 15 protected against TNF-induced apoptosis. These data
g TNF without prior HS (, n  30). Blood was withdrawn and demonstrate that HS pretreatment completely preventsanalyzed for NOx and IL-6 concentrations 1, 3, 6, 9, 12, or 24 hr
the TNF-induced tissue damage (apoptosis) at the siteafter TNF administration (n  6 per time point).
of the jejunum.
jejunum, and ileum) was removed and weighed with its HS-Induced Protection against TNF Toxicity Is Absent
content (n12), which was significantly high (p0.0001 in hsp70.1/ Mice
compared to mice treated with PBS). HS pretreatment To investigate whether induction of HSP70 is responsi-
ble for HS-conferred protection, we used hsp70.1/greatly prevented exudation (p  0.0001 compared to
Heat Shock Prevents TNF-Induced Lethality
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Figure 5. HS Pretreatment Prevents TNF-Induced Bowel Damage
Mice were kept at room temperature or subjected to HS and challenged i.v. after 12 hr with 15 g TNF. Parts of the jejunum were homogenized
for assessment of DNA fragmentation and DEVDase activity (A). Other parts of the jejunum were fixed and embedded in paraffin, followed by
hematoxylin/eosin staining (B–D), TUNEL assay (E–G), or immunohistochemistry (H–J). PBS-treated mice (B, E, and H), TNF-treated mice (C,
F, and I), and TNF-treated mice 12 hr after HS (D, G, and J) (scale bars, 10 m).
mice. First, we analyzed the induction of HSP70 in these we evaluated the application of HS induction in an antitu-
mor protocol. Since this experiment involves a 10 daymice after HS treatment. Wt and hsp70.1/ mice were
HS treatment, we investigated whether ten consecutiveHS treated and 12 hr later were sacrificed to remove
HS treatments led to a feedback on HSP70 induction,liver, jejunum, and colon. While induction of HSP70 is
resulting in lack of protection. To that end, mice (n very obvious in liver, jejunum, and colon of wt mice, no
11) were HS treated for 10 consecutive days and wereinduction whatsoever was found 12 hr after HS (Figure
injected i.v. with 15 g TNF 12 hr after the tenth HS6A, inset).
treatment. As controls, mice were treated with 15 gWt (n  13) and hsp70.1/ mice (n  12) were sub-
TNF 12 hr after a single HS treatment (n 12) or withoutjected to HS and 12 hr later were challenged with 15 g
HS treatment (n  12). To analyze HSP70 induction,TNF. As control groups, we also treated wt (n  13) and
liver, jejunum, and colon were removed from parallellyhsp70.1/ (n  12) mice without prior HS with 15 g
HS-treated mice at the time of TNF injection (12 hr afterTNF (we observed no difference in sensitivity to TNF
HS). A single HS treatment induced high HSP70 levels;between wt and hsp70.1/ mice; data not shown). HS
after ten consecutive HS treatments, the expression oftreatment significantly prevented TNF-induced lethality
HSP70 was still high, even higher as compared to ain wt mice (p  0.0001) (Figure 6A) but not in hsp70.1/
single HS treatment (Figure 7A, inset). Furthermore, themice (p 	 0.05) (Figure 6B).
increased number of HS treatments led to a significantTo study the role of HSP70 in the inhibition of TNF-
protection against TNF lethality, although statisticallyinduced hypothermia as well as in NO and IL-6 produc-
not better than a single HS treatment (Figure 7A). Wetion, wt (n  6) and hsp70.1/ mice (n  6) were HS
also observed a better protection against TNF-inducedsubjected and challenged 12 hr later with 15 g TNF.
hypothermia. Nine and twelve hours after TNF challenge,Wt (n  6) and hsp70.1/ mice (n  6) without prior
a significant difference in body temperature was foundHS were challenged with TNF as control groups. As
between mice treated ten times or only once with HSobserved before, hypothermia, NO, and IL-6 levels were
(p 0.0041 and p 0.0001 for 9 and 12 hr, respectively)significantly inhibited by HS in wt mice (Figure 6C; p 
(Figure 7B). These data indicate that repeated HS treat-0.004) but not at all in hsp70.1/ mice (Figure 6D, p 	
ments do not lead to downmodulation of hsp70 expres-0.05).
sion or tolerization against HSP70 induction and thatThese data clearly demonstrate that induction of
increased HSP70 levels provide a better protectionHSP70 by HS is responsible for inhibition of hypothermia
(dose response between HSP70 levels and degree ofas well as for NO and IL-6 induction.
protection).
In antitumor experiments, mice were inoculated s.c.
HS Application in an Antitumor Protocol with B16Bl6 cells on day 0 and divided randomly into
Inoculation of C57BL/6 mice with B16Bl6 melanoma three groups on day 9. One group (n  10) received
cells is a syngeneic tumor model. Application of TNF daily s.c. injections of PBS for 10 days. The HS group
in combination with IFN- induces regression of these (n  11) was treated s.c. with 10 g TNF in combination
tumors but is accompanied with high mortality (Brouck- with 5000 IU IFN- 12 hr after HS for 10 consecutive
days. Control mice (n  10) received ten daily injectionsaert et al., 1986). In order to reduce or inhibit this toxicity,
Immunity
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Figure 6. HS-Induced Protection Is Absent in hsp70.1/ Mice
(A–B) Wt mice (, n  13) and hsp70.1/ mice (, n  12) were HS treated and challenged i.v. after 12 hr with 15 g TNF. Control wt mice
(, n  13) and hsp70.1/ mice (, n  12) were injected with 15 g TNF without prior HS. Liver, jejunum, and colon were removed from
parallelly HS-treated animals 12 hr after HS. (inset) Western blot for HSP70 12 hr after HS.
(C–D). Wt and hsp70.1/ mice (both n  6) were HS treated and challenged i.v. after 12 hr with 15 g TNF. Wt and hsp70.1/ mice (both n 
6) were injected with 15 g TNF without prior HS. Twenty-four hours after challenge, body temperature was recorded, and blood was withdrawn
to determine NOx and IL-6 levels. NS, nonsignificant.
with TNF and IFN- without prior HS. The combination Discussion
of TNF and IFN- was administered s.c. in the vicinity
of the tumor and not i.v., since the former application TNF is successfully used in the clinic in combination
with IFN- and melphalan for isolated limb perfusionallows the best tumor regression. The tumor size index
(TSI) was recorded from day 10 (start treatment) until (Eggermont, 1998). Different pathologies have also been
associated with TNF. A role for TNF has been demon-day 19 (stop treatment). Lethality was followed up to 1
week after the last day of treatment (no further deaths strated in inflammatory bowel disease, since application
of a monoclonal antibody directed against TNF led tooccurred). Mice treated with PBS displayed drastic tu-
mor growth, while TNF/IFN- treatment led to complete improvement of the disease, both in an animal model
(Watkins et al., 1997) and in patients with Crohn’s dis-regression of the tumor (p  0.001 from day 14 as com-
pared to PBS-treated mice) (Figure 7C). HS pretreatment ease (D’Haens et al., 1999). TNF inhibitors and anti-TNF
antibodies have also proven their efficacy in treatingdid not inhibit this antitumor activity. From day 14, the
TSI was significantly different from the HS and PBS arthritis (Lorenz, 2000; Emery, 2001). In diabetes it is still
doubtful whether TNF plays a deleterious role (Hunger etgroups (p  0.001), while no statistical differences were
observed between the two TNF/IFN--treated groups. al., 1997) or a protective role (Cope et al., 1997).
We are studying several ways to inhibit the toxicityHS induction had a significantly protective effect against
lethality induced by a TNF/IFN- treatment (Figure 7D). induced by TNF. In the past, we have demonstrated that
acute phase proteins confer protection against TNF-A significant difference, both in survival time (p 0.0002)
and final lethality (p  0.0037), was found compared to induced toxicity and lethality (Libert et al., 1994, 1996;
Van Molle et al., 1997, 1999). In this report, we evaluatedTNF/IFN--treated mice without prior HS. These data
demonstrate that HS induction not only prevents TNF- the protective capacities of HS induction against TNF.
Subjecting mice to a HS treatment for 20 min at 42Cinduced lethality but also allows application of TNF in
combination with IFN- as a safe antitumor strategy. resulted in a remarkable increase in body temperature
Heat Shock Prevents TNF-Induced Lethality
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Figure 7. Repeated HS Treatments Do Not
Lead to Downregulation of HSP70 Expres-
sion, Still Confer Protection against TNF Le-
thality, and Allow Application in an Antitumor
Protocol
(A–B) Mice were subjected once (, n  12)
or ten consecutive times (, n  11) to HS
and challenged i.v. 12 hr later with 15 g TNF.
Controls were challenged with 15 g TNF
without prior HS (, n  12). Induction of
HSP70 12 hr after (last) HS was analyzed by
Western blot (inset: liver, jejunum, colon).
(C–D) Mice were inoculated s.c. with 6 
 105
B16Bl6 cells on day 0. From day 10 until day
19, mice were injected s.c. with PBS (, n 
10), 10 g TNF  5000 IU IFN- without HS
(, n  10) or 10 g TNF  5000 IU IFN- 12
hr after HS (, n  11).
and a strong induction of HSP70 in lung, liver, colon, representative of a lethal outcome (Libert et al., 1990).
The reduced production of IL-6 observed in this studyand jejunum. This was not shown before for jejunum and
colon. Induction was high 6 hr after HS treatment and could be mediated by glucocorticoids, since corticoste-
rone levels are increased 5-fold when rats are exposedremained high until 24–48 hr. We also demonstrate that
HS treatment confers significant protection against TNF- to 41C for 20 min (Alexandrova and Farkas, 1992) and
since we previously demonstrated that treatment ofinduced lethality when applied 12 hr but not 2, 24, or
48 hr before TNF administration. When mice were HS mice with the corticosteroid dexamethasone reduced
IL-6 levels induced by TNF (Libert et al., 1991) and pre-subjected 6 hr before the TNF challenge, we only ob-
served a marginal protection. vented TNF-induced lethality (Bertini et al., 1988; Libert
et al., 1991). However, in hsp70.1/ mice we observedWhen hsp70.1/ mice were treated with a whole-body
HS, we detected no HSP70 12 hr after HS. These data no inhibition by HS of TNF-induced hypothermia as well
as of NO and IL-6, indicating that HSP70 most probablyindicate that inactivation of one of the two inducible
hsp70 genes (in our case, hsp70.1) negatively influences affects IL-6 and NO induction independently of gluco-
corticoids. It has recently been shown that HSP70 inter-hsp70 induction. Traces of HSP70 were found 6 hr after
HS in hsp70.1/ mice, probably due to expression of acts with Bag-1 (Song et al., 2001). Under physiological
conditions, Bag-1 interacts with Raf-1 (Wang et al.,the remaining hsp70.3 gene. Reduced levels of HSP70
6 hr after HS in hsp70.1/ mice and hsp70.3/ mice 1996). The latter interacts with mitogen-activated pro-
tein kinase, which leads to activation of transcriptionhave recently been shown, but without investigation of
hsp70 induction at later time points after HS (Huang et factors involved in cell growth and differentiation (Mor-
rison and Cutler, 1997). Under HS conditions, HSP70al., 2001). Since we show that hsp70.1/ mice are no
longer protected against TNF lethality after HS, we un- and Raf-1 have been proposed to compete for Bag-1
binding, resulting in displacement of Bag-1/Raf-1 byambiguously prove that HSP70 induction is perhaps suf-
ficient but certainly required for HS-mediated pro- Bag-1/HSP70 and arrest of DNA synthesis (Song et al.,
2001). Hence, HSP70 may also affect the activation oftection.
Administration of TNF to mice results in hypothermia transcription factors involved in the induction of IL-6
and inducible NO synthase.and a strong induction of IL-6 and NO, which leads to
hypotension and which is reflected in high levels of ni- I.v. administration of relatively high doses of TNF in
rats and mice results in tissue damage in the lungs,trite and nitrate and IL-6 in the serum (Van Molle et
al., 1997). We here show that HS induction significantly kidney, and intestine (Tracey et al., 1986). More specifi-
cally, the duodenum (Piguet et al., 1998) and the jejunuminhibits hypothermia and NO induction. There is also a
strong effect on IL-6 induction. While control mice dis- (our unpublished data) are important targets for TNF-
induced toxicity, as observed by swelling, shortening ofplay high levels of IL-6, HS-pretreated animals show
significantly lower levels of IL-6, 3 hr after TNF challenge. the villi, crypt loss, and epithelial cell apoptosis. When
we subjected mice to HS 12 hr before a lethal TNFIt has been speculated that a strong IL-6 induction is
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challenge, we observed a clear reduction of the TNF- as mentioned before, hyperthermia is a rational method
induced damage at the jejunum, accompanied with fairly to cure malignancies. Heat treatment is also applied in
reduced apoptosis of epithelial cells. We showed that isolated limb perfusion, the first hyperthermic applica-
HS significantly prevents exudation and inhibits apo- tion dating back to 1958 (Creech et al., 1958). In hyper-
ptosis and caspase activation in the jejunum. We also thermic isolated limb perfusion, TNF is combined with
demonstrated that TUNEL-positive cells are not present IFN- and melphalan under mild conditions from 39C
after HS preconditioning and that those cells express to 40C for 1 hr (Minor et al., 1985; Olieman et al., 1999).
HSP70 as visualized by immunohistochemistry. It has One might speculate that these hyperthermic conditions
recently been reported that HSP70 in vitro inhibits the induce HSP70, which in turn provides a protective mech-
recruitment of procaspase-9 to the Apaf-1/apoptosome anism against the toxicity accompanying treatments
complex, thereby preventing cytochrome c and ATP- with TNF/IFN-/melphalan.
induced apoptosis on cytosolic extracts of Jurkat T cells We conclude that whole-body HS of mice confers
(Beere et al., 2000; Saleh et al., 2000). Hence, we may protection against TNF-induced lethality and toxicity
postulate that the protection conferred by HS at the and that this HS treatment coincides with a strong induc-
jejunum is based on the inhibition of TNF-induced apo- tion of HSP70 in the jejunum, which is a primary target
ptosis of epithelial cells by HSP70 induction. In TNF- of TNF toxicity. Based on our studies with hsp70.1/
treated animals, apoptosis of epithelial cells finally leads mice we believe that HSP70 itself is at least necessary
to loss in architecture of the intestine. This might result for the conferred protection. We also show that HS treat-
in an increased uptake in the circulation of gut-derived ment prevents TNF-induced IL-6 production in the se-
endotoxins and in a drastic sensitization to TNF (Neilson rum and TNF-induced damage at the jejunum. Applying
et al., 1989; Fox et al., 1996). Therefore, mice may die HS in an antitumor protocol did not inhibit the antitumor
from endotoxins released by bacteria. When mice are capacity of a combination of TNF and IFN- but pre-
pretreated with HS, the architecture of the small intes- vented the subsequent lethality. This might open new
tine is completely preserved, thereby preventing such perspectives for the application of HS treatment in the
an increased uptake. A possible argument for this hy- clinic.
pothesis is that pretreatment of mice with tetracycline
added to the drinking water for 3 days (sufficient to Experimental Procedures
sterilize the gut) significantly prevents TNF-induced le-
thality (2/9 for tetracycline-pretreated mice versus 8/10 Animals
Female C57BL/6 mice were obtained from Iffa-Credo (Saint Ger-for control mice after TNF challenge, p  0.023; our
main-sur-l’Arbresle, France) and were used at the age of 8–10unpublished data).
weeks. Hsp70.1/ mice were bred as homozygotes in our facilities.Considering that HS induction appears to have broad-
Mice were kept in a temperature-controlled, air-conditioned animalrange protection, we evaluated the application of HS in
house with 14-10 hr light/dark cycles; they received food and water
an antitumor protocol. It has been recognized for years ad libitum.
that fever has beneficial effects on survival during infec-
tion (Covert and Reynolds, 1977; Kluger, 1991). Further-
Generation of hsp70.1/ Mice
more, systemic application of hyperthermia has been The mouse hsp70.1 genomic clone was isolated from a 129 strain
used to treat patients with specific types of malignancies mouse genomic library (Stratagene, La Jolla, CA) by a standard
(Robins et al., 1989). In this report, we show that a daily plaque hybridization procedure using a 3-noncoding sequence of
the hsp70.1 gene as specific probe. The targeting vector was con-HS treatment does not inhibit the antitumor activity of
structed as follows. The hsp70.1-coding sequence was replacedTNF and IFN-. We further also show that repeated HS
with the PMC1-NeoR gene (Stratagene) fragment from which thetreatments lead not only to higher expression levels of
promoter region was removed. When homologous recombinationHSP70 and no tolerance to HSP70 but also to a better
occurs in a correct way, the NeoR fusion gene is expressed in-frame
protection against TNF toxicity. Mice that are HS-treated starting from the hsp70.1 promoter. E14 ES cells were transfected
prior to TNF/IFN- treatment are less susceptible to loss with 30 g of the linear targeting vector DNA per 5 
 107 cells by
in body weight and, more importantly, are significantly electroporation (800V, 300 mF; Bio-Rad Laboratories, Richmond,
CA). G418 selection (150 mg/ml) was initiated 24 hr after electropora-protected against the induced lethality. Daily treatment
tion; G418-resistant colonies were obtained after 7–10 days of selec-of mice with TNF and IFN- results in apoptotic and
tion. The targeted disruption was confirmed by Southern blot analy-necrotic damage in several organs, which is prevented
sis. Chimeric mice were produced by injection of ES cells into F1by HS-induced HSP70 (our unpublished data). It might
(C57BL/6J x CBA/CaLac) blastocysts. Heterozygotes for the tar-
seem contradictory that HS treatment and induction of geted allele were obtained by breeding of chimeras with C57BL/6J
HSP70 inhibit the lethality and not the antitumoral ca- mice (CleaJapan, Tokyo, Japan). Finally, homozygote knockout
pacity of TNF and IFN-. Overexpression of HSP70 in mice were produced by interbreeding of heterozygotes.
tumor cell lines has been demonstrated to protect these
cells against TNF toxicity (Ja¨a¨ttela¨ et al., 1989), though Reagents
such studies only involved the direct effect of TNF. We Recombinant murine TNF and murine IFN-were produced in Esch-
have good reasons to believe that in vivo tumor killing erichia coli and purified to homogeneity in the Ghent laboratory.
Two different batches of TNF were used. For antitumor experiments,by the combination of TNF and IFN- is, at least partially,
TNF had a specific activity of 9.1 
 107 IU/mg, the endotoxin con-mediated by the host and is not solely a direct cytotoxic
tamination being 100 U/mg. In all other experiments, TNF with aeffect on tumor cells (Brouckaert et al., 1986). Thus, it
specific activity of 1.2 
 109 IU/mg and an endotoxin contamination
is possible that host-mediated effects are not inhibited of6 U/mg was used. IFN- had a specific activity of 1.1
 108 IU/mg.
by HSP70, in a sense that increased HSP70 levels in The endotoxin contamination was assessed in a chromogenic Limu-
tumor cells do not inhibit the antitumoral activity of TNF lus amebocyte lysate assay (Coatest; Chromogenix, Stockholm,
Sweden). Paraffin was purchased from Sigma Chemical Co. (St.and IFN-. These results open a link to the clinic where,
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Louis, MO). Histo-clear was obtained from National Diagnostics Western Blot
Fifty micrograms of total protein of the different tissue homogenates(Atlanta, GA).
was loaded on a 7.5% polyacrylamide gel and run at 150V. After
electrophoretic separation, proteins were blotted on a nitrocelluloseHS Induction
membrane (Schleicher & Schuell, Dassel, Germany) for 2 hr at 120An empty mouse cage and a tray filled with water were placed in a
mA. Blots were blocked with 1% BSA and 0.1% Triton X-100 over-hybridization oven (Amersham Pharmacia Biotech, Rainham, UK)
night at 4C. They were incubated for 2 hr at room temperature withfor at least 2 hr at 42C. These conditions should provide a relative
a biotinylated mouse anti-HSP70 antibody (SPA-810B; Stressgenhumidity of 75% (Dietrich et al., 2000), which favors efficient HS
Biotechnologies Corporation, Victoria, Canada) and diluted 1/3000(Fujio et al., 1987; Nowak et al., 1990). Mice were placed in the cage
in BSA/Triton X-100. After three washes, blots were incubated withfor 20 min at 42C, after which they were transferred to a clean cage
streptavidin-AP (1/1500; BioSource International, Camarillo, CA) andat room temperature.
developed with NBT/BCIP (Roche Molecular Biochemicals, Basel,
Switzerland).Injections and Blood Collections
I.v. injections were performed in 0.2 ml and s.c. injections in 0.1 ml.
DNA Fragmentation ELISAPrior to injection, cytokines and reagents were diluted in an LPS-
Twenty percent homogenates of jejunum samples were made infree isotonic solution. Blood was taken by cardial puncture during
glycerol buffer supplemented with 1 mM PMSF, 0.3 mM aprotenin,avertin anesthesia. Blood was allowed to clot for 30 min at 37C
1 mM leupeptin, and 1 mM oxidized glutathione and centrifuged forand for at least 1 hr at 4C, followed by two centrifugations at
30 min at 13,000
 g. The supernatant was stored at 20C. DNA20,000
 g for 3 min. Serum was stored at 20C until use.
fragmentation was quantified by immunochemical determination of
histone-complexed DNA fragments in a microtiter plate as pre-Tissue Embedding, Tissue Sectioning, and Staining
viously described (Salgame et al., 1997).Tissues were removed after cervical dislocation and immediately
fixed in a 4% paraformaldehyde solution at room temperature. After
passing through baths of 50%, 70%, 95%, and 100% ethanol and Fluorogenic Substrate Assay for Caspase Activity
100% Histo-clear, tissues were embedded in paraffin. Four micro- Caspase-like activities were determined by incubation of jejunum
meter sections were prepared with a microtome, followed by hema- homogenate (containing 50 g of total protein) with 50 M of the
toxylin/eosin staining. TUNEL staining was performed with the fluorogenic substrate Ac-DEVD-amc (Peptide Institute, Osaka, Ja-
Deadend colorimetric apoptosis detection system (Promega Biotec, pan) in 150 l cell-free system buffer containing 10 mM HEPES [pH
Madison, WI). Tissue sections were treated according to the manu- 7.4], 220 mM mannitol, 68 mM sucrose, 2 mM NaCl, 2.5 mM KH2PO4,
facturer’s instructions. In brief, samples were treated for 10 min with 0.5 mM EGTA, 2 mM MgCl2, 5 mM pyruvate, 0.1 mM PMSF, and 1
a proteinase K solution and then incubated with TdT enzyme and mM DTT. Release of fluorescent amc was measured for 1 hr at
biotinylated dUTPs for 60 min at 37C. After blocking the endoge- 2 min intervals by fluorometry (Cytofluor; PerSeptive Biosystems,
nous peroxidase activity, sections were incubated with horseradish Cambridge, MA). Data are expressed as units of cleavable ac-DEVD-
peroxidase conjugated to streptavidin and developed with diamino- amc activity after application of a serial dilution of free amc as a
benzidine, yielding dark brown staining of nuclei. standard, where one unit is the activity releasing 1 pmol/amc in 1
For immunohistochemistry, paraffin sections were incubated min at 30C.
overnight at room temperature with a goat anti-mouse HSP70 anti-
body (1/50; Santa Cruz Biotechnology, Santa Cruz, CA). A rabbit Statistical Analysis
anti-goat biotin-coupled antibody was used for 45 min at room Survival curves (Kaplan-Meyer plots) were compared using a log-
temperature (1/400) as secondary antibody. The signal was ampli- rank test. Final lethality was compared with a chi2 test. Means 
fied by tyramide signal amplification (Du Pont, Wilmington, DE); SD were compared with a Student’s t test. *, **, and *** represent
visualization was obtained with an AEC chromogen substrate p  0.01–0.05, p  0.001–0.01, and p  0.001, respectively.
(Dako, Carpinteria, CA).
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